

ACOG PRACTICE BULLETIN

Clinical Management Guidelines for Obstetrician–Gynecologists

NUMBER 229

(Replaces Practice Bulletin Number 145, July 2014)

Committee on Practice Bulletins—Obstetrics. This Practice Bulletin was developed by the Committee on Practice Bulletins—Obstetrics with the assistance of Dwight J. Rouse, MD.

INTERIM UPDATE: The content in this Practice Bulletin has been updated as highlighted (or removed as necessary) to reflect a limited, focused change to align with American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 828, *Indications for Outpatient Antenatal Fetal Surveillance*, and provide updated information regarding fetal kick counts.

Antepartum Fetal Surveillance

The goal of antepartum fetal surveillance is to **reduce the risk of stillbirth**. Antepartum fetal surveillance techniques based on assessment of fetal heart rate (FHR) patterns have been in clinical use for almost four decades and are used along with real-time ultrasonography and umbilical artery Doppler velocimetry to evaluate fetal well-being. Antepartum fetal surveillance techniques are routinely used to assess the risk of fetal death in pregnancies complicated by preexisting maternal conditions (eg, diabetes mellitus) as well as those in which complications have developed (eg, fetal growth restriction). The purpose of this document is to provide a review of the current indications for and techniques of antepartum fetal surveillance and outline management guidelines for antepartum fetal surveillance that are consistent with the best scientific evidence.

Background

Physiology of Fetal Heart Response and Fetal Behavioral State Alteration

In animals and humans, FHR pattern, level of activity, and degree of muscular tone are sensitive to hypoxemia and acidemia (1–4). Redistribution of fetal blood flow in response to hypoxemia may result in diminished renal perfusion and oligohydramnios (5). Surveillance techniques such as cardiotocography, real-time ultrasonography, and maternal perception of fetal movement can identify the fetus that may be undergoing some degree of uteroplacental compromise. Identification of suspected fetal compromise provides the opportunity to intervene before progressive metabolic acidosis results in fetal death. However, acute, catastrophic changes in fetal status, such as those that can occur with placental abruption or an umbilical cord accident, are generally not predicted by tests of fetal well-being. Therefore, fetal deaths from such events are less amenable to prevention.

In humans, the range of normal umbilical blood gas parameters has been established by cordocentesis per-

formed in pregnancies in which the fetus ultimately proved to be healthy, and ranges vary by gestational age (6). Although the degree of hypoxemia and acidemia at which various indices of fetal well-being become abnormal is not known with precision, it can be estimated based on data from published studies. In one investigation, the fetal surveillance was performed immediately before cordocentesis. Fetuses with an abnormal test result were found to have a mean (\pm standard deviation) umbilical vein blood pH of 7.28 (\pm 0.11). Cessation of fetal movement appears to occur at lower pH levels; fetuses with abnormal movement were found to have a mean umbilical vein blood pH of 7.16 (\pm 0.08) (7). Thus, a reasonable correlation between certain measurable aspects of FHR and behavior and evidence of fetal metabolic compromise can be inferred.

Although abnormal fetal surveillance results may be associated with acidemia or hypoxemia, they reflect neither the severity nor duration of acid–base disturbance. The degree and duration of acidemia is weakly correlated with adverse short-term and long-term



neonatal outcomes. Furthermore, factors other than acid-base and oxygenation status (eg, prematurity, fetal sleep-wake cycle, maternal medication exposure, maternal smoking, and fetal central nervous system abnormalities) can adversely affect biophysical parameters (8, 9).

Antepartum Fetal Surveillance Techniques

Several antepartum fetal surveillance techniques (tests) are in clinical use. These include maternal perception of fetal movement, contraction stress test (CST), nonstress test (NST), biophysical profile (BPP), modified BPP, and umbilical artery Doppler velocimetry.

Maternal–Fetal Movement Assessment

A decrease in the maternal perception of fetal movement may precede fetal death, in some cases by several days (10). This observation provides the rationale for fetal movement assessment by the mother (“kick counts”) as a means of antepartum fetal surveillance. However, a meta-analysis that included five randomized controlled trials (RCT) and more than 450,000 fetuses found no difference in perinatal outcome between the group that underwent fetal kick counts and the group that did not (11). The incidence of perinatal death was 0.54% (1,252/229,943) in the fetal kick counts group and 0.59% (944/159,755) in the control group (relative risk [RR], 0.92; 95% CI 0.85–1.00). There were no statistical differences between other perinatal adverse outcomes; however, there were weak but statistically significant increases in preterm delivery (7.6% versus 7.1%; RR 1.07, 95% CI 1.05–1.10), induction of labor (36.6% versus 31.6%; RR 1.15, 95% CI 1.09–1.22), and cesarean delivery (28.2% versus 25.3%; RR 1.11, 95% CI 1.10–1.12) in the fetal kick counts group. One RCT of more than 400,000 fetuses (the Follow-up Investigation Rhythm Management [AFFIRM] trial) contributed 82% of the data and information regarding the characteristics of included women, and the techniques used for surveillance and follow up were limited. The authors of the meta-analysis concluded that more trials of a similar size are necessary to determine whether there is benefit to this approach, and warn that there may be possible harm related to iatrogenic delivery (12).

Although several counting protocols have been used, neither the optimal number of movements nor the ideal duration for counting movements has been defined. Thus, numerous protocols have been reported and appear to be acceptable. In one approach, the woman was instructed to lie on her side and count distinct fetal movements (13). Perception of 10 distinct movements in a period of up to 2 hours was considered reassuring. The count was discontinued once 10 movements were perceived. The mean time interval to perceive 10 movements was 20.9

(±18.1) minutes. In another approach, women were instructed to count fetal movements for 1 hour three times per week (14). The count was considered reassuring if it equaled or exceeded the woman’s previously established baseline count. Thus, regardless of the fetal movement approach used, in the absence of a reassuring count, further fetal assessment is recommended.

Contraction Stress Test

The CST is based on the response of the FHR to uterine contractions. It relies on the premise that fetal oxygenation will be transiently worsened by uterine contractions. In the suboptimally oxygenated fetus, the resultant intermittent worsening in oxygenation will, in turn, lead to the FHR pattern of late decelerations. Uterine contractions also may produce a pattern of variable decelerations caused by fetal umbilical cord compression, which in some cases is associated with oligohydramnios.

With the patient in the lateral recumbent position, the FHR and uterine contractions are simultaneously recorded with an external fetal monitor. An adequate uterine contraction pattern is present when at least three contractions persist for at least 40 seconds each in a 10-minute period. Uterine stimulation is not necessary if the patient is having spontaneous uterine contractions of adequate frequency. If fewer than three contractions of 40 seconds’ duration occur in 10 minutes, contractions are induced with either nipple stimulation or intravenous oxytocin. A spontaneous CST can be considered if the adequate number and strength of contractions are noted in the 10-minute time frame.

Nipple stimulation usually is successful in inducing an adequate contraction pattern and allows completion of testing in approximately one half of the time required than when intravenous oxytocin is used (15). The CST is interpreted according to the presence or absence of late FHR decelerations (16). A late deceleration is defined as a visually apparent and usually symmetrical gradual decrease and return to baseline FHR in association with uterine contractions, with the time from onset of the deceleration to its FHR nadir as 30 seconds or longer. The deceleration is delayed in timing, with the nadir of the deceleration occurring after the peak of the contraction. In most cases, the onset, nadir, and recovery of the deceleration occur after the beginning, peak, and ending of the contraction, respectively (17). The results of the CST are categorized as follows:

- Negative: no late or significant variable decelerations
- Positive: late decelerations after 50% or more of contractions (even if the contraction frequency is fewer than three in 10 minutes)



- Equivocal–suspicious: intermittent late decelerations or significant variable decelerations
- Equivocal: FHR decelerations that occur in the presence of contractions more frequent than every 2 minutes or lasting longer than 90 seconds
- Unsatisfactory: fewer than three contractions in 10 minutes or an uninterpretable tracing

The CST is a safe and effective method of investigating FHR nonreactivity in preterm gestations (18). Relative contraindications to the CST generally include conditions that also are contraindications to labor or vaginal delivery (19).

Nonstress Test

The NST is based on the premise that the heart rate of a fetus that is not acidotic or neurologically depressed will temporarily accelerate with fetal movement. Heart rate reactivity is thought to be a good indicator of normal fetal autonomic function. Loss of reactivity is most commonly associated with a fetal sleep cycle but may result from any cause of central nervous system depression, including fetal acidemia.

The patient may be positioned in either the semi-Fowler position (sitting with the head elevated 30 degrees) or lateral recumbent position. In one small randomized study, it took less time to obtain a reactive NST when patients were placed in the semi-Fowler position (20). The FHR is monitored with an external transducer. The tracing is observed for FHR accelerations that peak (but do not necessarily remain) at least 15 beats per minute above the baseline and last 15 seconds from baseline to baseline. The NST should be conducted for at least 20 minutes, but it may be necessary to monitor the tracing for 40 minutes or longer to take into account the variations of the fetal sleep–wake cycle. Vibroacoustic stimulation may elicit FHR accelerations that are valid in the prediction of fetal well-being. Such stimulation offers the advantage of safely reducing the frequency of nonreactive NSTs by 40% and the overall testing time by almost 7 minutes without compromising detection of the acidotic fetus (21–24). To perform vibroacoustic stimulation, the device is positioned on the maternal abdomen and a stimulus is applied for 1–2 seconds. If vibroacoustic stimulation fails to elicit a response, it may be repeated up to three times for progressively longer durations of up to 3 seconds.

Nonstress test results are categorized as reactive or nonreactive. Various definitions of reactivity have been used. The most common definition of a reactive, or normal, NST is if there are two or more FHR accelerations (as previously defined) within a 20-minute period (25). A nonreactive NST is one that lacks sufficient FHR

accelerations over a 40-minute period. The NST of the normal preterm fetus is frequently nonreactive: from 24 weeks to 28 weeks of gestation, up to 50% of NSTs may not be reactive (26), and from 28 weeks to 32 weeks of gestation, 15% of NSTs are not reactive (17, 27, 28). Thus, the predictive value of NSTs based on a lower threshold for accelerations (at least 10 beats per minute above the baseline and at least 10 seconds from baseline to baseline) has been evaluated in pregnancies at less than 32 weeks of gestation and has been found to sufficiently predict fetal well-being (29, 30). Variable decelerations may be observed in up to 50% of NSTs (31). Variable decelerations that are nonrepetitive and brief (less than 30 seconds) are not associated with fetal compromise or the need for obstetric intervention (31). Repetitive variable decelerations (at least three in 20 minutes), even if mild, have been associated with an increased risk of cesarean delivery for a nonreassuring intrapartum FHR pattern (32, 33). Fetal heart rate decelerations during an NST that persist for 1 minute or longer are associated with a markedly increased risk of both cesarean delivery for a nonreassuring FHR pattern and fetal demise (34–36). In this setting, the decision to deliver should be made with consideration of whether the benefits outweigh the potential risks of expectant management.

Biophysical Profile

The BPP consists of an NST combined with four observations made by real-time ultrasonography (37). Thus, the BPP comprises five components:

1. Nonstress test—may be omitted without compromising test validity if the results of all four ultrasound components of the BPP are normal (37)
2. Fetal breathing movements—one or more episodes of rhythmic fetal breathing movements of 30 seconds or more within 30 minutes
3. Fetal movement—three or more discrete body or limb movements within 30 minutes
4. Fetal tone—one or more episodes of extension of a fetal extremity with return to flexion, or opening or closing of a hand
5. Determination of the amniotic fluid volume—a single deepest vertical pocket greater than 2 cm is considered evidence of adequate amniotic fluid (38–40)

Each of the five components is assigned a score of either 2 (present, as previously defined) or 0 (not present). A composite score of 8 or 10 is normal, a score of 6 is considered equivocal, and a score of 4 or less is abnormal. Regardless of the composite score, oligohydramnios (defined as an amniotic fluid volume of 2 cm or



less in the single deepest vertical pocket) should prompt further evaluation (39, 41).

Although oligohydramnios has been commonly defined as a single deepest vertical pocket of amniotic fluid of 2 cm or less (not containing umbilical cord or fetal extremities) and an amniotic fluid index of 5 cm or less, available data from randomized control trials (RCTs) support the use of the deepest vertical pocket of amniotic fluid volume of 2 cm or less to diagnose oligohydramnios (38–40, 42, 43).

Modified Biophysical Profile

In the late second-trimester or third-trimester fetus, amniotic fluid volume reflects fetal urine production. Placental dysfunction may result in diminished fetal renal perfusion, leading to oligohydramnios (5). Amniotic fluid volume assessment can, therefore, be used to evaluate uteroplacental function. This observation fostered the development of what has come to be termed the “modified BPP” as a primary mode of antepartum fetal surveillance. The modified BPP combines the NST, as a short-term indicator of fetal acid–base status, with an amniotic fluid volume assessment, as an indicator of long-term placental function (21). Thus, the results of the modified BPP are considered normal if the NST is reactive and the amniotic fluid volume is greater than 2 cm in the deepest vertical pocket and are considered abnormal if either the NST is nonreactive or amniotic fluid volume in the deepest vertical pocket is 2 cm or less (ie, oligohydramnios is present).

Umbilical Artery Doppler Velocimetry

Doppler ultrasonography is a noninvasive technique used to assess the hemodynamic components of vascular resistance in pregnancies complicated by fetal growth restriction. Umbilical artery Doppler velocimetry has been adapted for use as a technique of fetal surveillance for the growth-restricted fetus, based on the observation that flow velocity waveforms in the umbilical artery of normally growing fetuses differ from those of growth-restricted fetuses. Specifically, the umbilical flow velocity waveform of normally growing fetuses is characterized by high-velocity diastolic flow, whereas in growth-restricted fetuses, there is decreased umbilical artery diastolic flow (44–46). In some cases of severe fetal growth restriction, diastolic flow is absent or even reversed. The perinatal mortality rate in such pregnancies is significantly increased (47). Abnormal flow velocity waveforms have been correlated histopathologically with small-artery obliteration in placental tertiary villi and functionally with fetal hypoxemia and acidemia as well as with perinatal morbidity and mortality (47–49). Com-

monly measured flow indices, based on the characteristics of peak systolic velocity and frequency shift (S), end-diastolic frequency shift (D), and mean peak frequency shift over the cardiac cycle (A), include the following:

- Systolic to diastolic ratio (S/D)
- Resistance index (S-D/S)
- Pulsatility index (S-D/A)

Randomized studies on the utility of umbilical artery Doppler velocimetry generally have defined abnormal flow as either absent or reversed end-diastolic flow (50–58). To maximize interpretability, multiple waveforms should be assessed, and wall-filter settings should be set low enough (typically less than 150 Hz) to avoid masking diastolic flow. Currently, there is no evidence that umbilical artery Doppler velocimetry provides information about fetal well-being in the fetus with normal growth.

Clinical Considerations and Recommendations

► *How reassuring is a normal antepartum fetal surveillance result?*

In most cases, a normal antepartum fetal test result is highly reassuring, as reflected in the low false-negative rate of antepartum fetal surveillance, defined as the incidence of stillbirth occurring within 1 week of a normal test result. The stillbirth rate, corrected for lethal congenital anomalies and unpredictable causes of fetal demise, was 1.9 per 1,000 in the largest series of NSTs (5,861) versus 0.3 per 1,000 in 12,656 CSTs, 0.8 per 1,000 in 44,828 BPPs, and 0.8 per 1,000 in 54,617 modified BPPs (16, 22, 59). Based on these data, the negative predictive value is 99.8% for the NST and is greater than 99.9% for the CST, BPP, and modified BPP. Although similar data from a large series are not available for umbilical artery Doppler velocimetry, in one randomized clinical trial among women with pregnancies complicated by fetal growth restriction, no stillbirths occurred in 214 pregnancies in which umbilical artery Doppler velocimetry was the primary means of antepartum fetal surveillance (negative predictive value of 100%) (51). The low false-negative rate of these tests depends on an appropriate response to any significant deterioration in the maternal clinical status, including retesting of the fetal condition. As previously mentioned, these tests generally do not predict stillbirths related to acute changes in maternal–fetal status, such as those that occur with abruptio placentae or an umbilical cord accident. Moreover, recent normal antepartum fetal test



results should not preclude the use of intrapartum fetal monitoring.

► ***Is there evidence that antepartum fetal surveillance decreases the risk of fetal demise or otherwise improves perinatal outcomes?***

Evidence for the value of antepartum fetal surveillance is circumstantial and rests principally on the observation that antepartum fetal surveillance has been consistently associated with rates of fetal death that are substantially lower than the rates of fetal death in both untested (and presumably lower-risk) contemporaneous pregnancies from the same institutions and pregnancies with similar complicating factors that were managed before the advent of currently used techniques of antepartum fetal surveillance (historic controls) (21, 22, 60). There is a lack of high-quality evidence from RCTs that antepartum fetal surveillance decreases the risk of fetal death (61, 62). A definitive evaluation of antepartum fetal surveillance in RCTs (which would require the random allocation of pregnant patients to prenatal care that included antepartum fetal surveillance versus prenatal care that did not include antepartum fetal surveillance) is unlikely to be conducted in a setting that can be generalized to current U.S. obstetric practice. In spite of its unproven value, antepartum fetal surveillance is widely integrated into clinical practice in the developed world.

► ***What are the indications for antepartum fetal surveillance?***

Because antepartum fetal surveillance results have not been definitively demonstrated to improve perinatal outcome, all indications for antepartum testing must be considered somewhat relative. In general, antepartum fetal surveillance has been used in pregnancies in which the risk of antepartum fetal demise is increased. See ACOG Committee Opinion No. 828, *Indications for Outpatient Antenatal Fetal Surveillance*, Table 1 for examples of indications for antepartum fetal surveillance.

► ***When during gestation should antepartum fetal surveillance be initiated?***

As with all testing and interventions, shared decision making between the pregnant individual and the clinician is critically important when considering or offering antenatal fetal surveillance for individuals with pregnancies at high risk for stillbirth or with multiple comorbidities that increase the risk of stillbirth. This can be particularly important in situations that involve fetal structural or genetic anomalies, or when initiating antenatal fetal surveillance around the threshold of viability, where the

pregnant individual's goals for pregnancy care are critical in decision making (63). Choosing the appropriate point in gestation to begin antepartum fetal testing depends on several considerations, including the prognosis for neonatal survival, the risk of fetal death, the severity of maternal disease, and the potential for iatrogenic prematurity complications resulting from false-positive test results. The importance of the last consideration is illustrated by the experience of one large center, in which 60% of infants delivered because of an abnormal antepartum test result had no evidence of short-term or long-term fetal compromise (22). Both theoretic models and large clinical studies suggest that initiating antepartum fetal testing at 32 0/7 weeks of gestation or later is appropriate for most at-risk patients (63–66). However, in pregnancies with multiple or particularly worrisome high-risk conditions (eg, chronic hypertension with suspected fetal growth restriction), testing might begin at a gestational age when delivery would be considered for perinatal benefit (67–72).

► ***What is the recommended frequency of testing?***

There are no large clinical trials to guide the frequency of testing, and thus, the optimal frequency remains unknown; it depends on several factors and should be individualized and based on clinical judgment. If the indication for testing is not persistent (eg, a single episode of decreased fetal movement followed by reassuring testing in an otherwise uncomplicated pregnancy), testing need not be repeated. When the clinical condition that prompted fetal testing persists, the testing should be repeated periodically to monitor for continued fetal well-being until delivery. If the maternal medical condition is stable and test results are reassuring, tests of fetal well-being (NST, BPP, modified BPP, or CST) are typically repeated at weekly intervals (19, 22); however, in the presence of certain high-risk conditions, some investigators have performed more frequent testing, although the optimal regimen has not been established. See ACOG Committee Opinion No. 828, *Indications for Outpatient Antenatal Fetal Surveillance*.

In pregnancies complicated by fetal growth restriction, the optimal interval for fetal growth assessment and the optimal surveillance regimen have not been established. Most growth-restricted fetuses can be adequately evaluated with once or twice weekly antenatal surveillance incorporating weekly BPP and Doppler assessments and serial ultrasonography for growth every 3–4 weeks; ultrasonographic assessment of growth should not be performed more frequently than every 2 weeks because the inherent error associated with ultrasonographic measurements can



preclude an accurate assessment of interval growth (63, 73, 74). Any significant change in maternal or fetal status requires further reevaluation (see ACOG Practice Bulletin No. 227, *Fetal Growth Restriction*).

► ***What is the recommended management of an abnormal antepartum fetal test result?***

An abnormal antepartum fetal test result should always be considered in the context of the overall clinical picture. Certain acute maternal conditions (eg, diabetic ketoacidosis or pneumonia with hypoxemia) can result in abnormal test results, which generally will normalize as the maternal condition improves. In these circumstances, correcting the maternal condition and retesting the fetus may be appropriate.

In cases in which an abnormal test result is not associated with any clinical evidence of acute and potentially reversible worsening in the maternal status, a stepwise approach to the investigation of the fetal condition should be undertaken. Because antepartum fetal surveillance tests have high false-positive rates and low positive predictive values, abnormal test results are usually followed by another test or delivery based on consideration of test results, maternal and fetal condition, and gestational age (25, 75). Such an approach takes advantage of the high negative predictive value generally exhibited by all commonly used antepartum tests and minimizes the potential for unnecessary delivery based on a single false-positive (ie, false-abnormal) test result. Therefore, the response to an abnormal test result should be tailored to the clinical situation.

Maternal reports of decreased fetal movement should be evaluated by an NST, CST, BPP, or modified BPP. Abnormal results from an NST or from a modified BPP generally should be followed by additional testing with either a CST or a BPP. A BPP score of 6 out of 10 is considered equivocal and should prompt further evaluation or delivery based on gestational age. In a fetus at or beyond 37 0/7 weeks of gestation, this score generally should prompt further evaluation and consideration of delivery, whereas in the fetus at less than 37 0/7 weeks of gestation, it should result in a repeat BPP in 24 hours (39). A BPP score of 4 usually indicates that delivery is warranted, although in pregnancies at less than 32 0/7 weeks of gestation, management should be individualized, and extended monitoring may be appropriate. In most circumstances, a BPP score of less than 4 should result in delivery. If delivery is not planned (eg, given early gestational age), then antenatal surveillance should not be performed because the results will not inform management.

In the absence of obstetric contraindications, delivery of the fetus with an abnormal test result often may be

attempted by induction of labor, with continuous intrapartum monitoring of the FHR and uterine contractions.

► ***How should a finding of oligohydramnios affect the decision for delivery?***

Amniotic fluid volume is estimated using ultrasonography. Commonly used definitions of oligohydramnios include a single deepest vertical pocket of amniotic fluid of 2 cm or less (not containing umbilical cord or fetal extremities) and an amniotic fluid index of 5 cm or less (38, 39, 42). However, the use of a percentile of amniotic fluid should not be used in management decisions. The available data from RCTs indicate that the use of the deepest vertical pocket measurement, as opposed to the amniotic fluid index, to diagnose oligohydramnios is associated with a reduction in unnecessary interventions without an increase in adverse perinatal outcomes (40, 43).

Determining when to intervene for oligohydramnios depends on several factors, including gestational age, maternal condition, and fetal clinical condition as determined by other indices of fetal well-being. Because rupture of the fetal membranes can cause diminished amniotic fluid volume, an evaluation for membrane rupture in the setting of oligohydramnios may be appropriate; correspondingly, if membrane rupture is documented, a low amniotic fluid measurement can no longer be considered valid for prediction of diminished placental function. In the setting of otherwise uncomplicated isolated and persistent oligohydramnios (deepest vertical pocket measurement less than 2 cm), delivery at 36 0/7–37 6/7 weeks of gestation or at diagnosis if diagnosed later is recommended (76, 77). In pregnancies at less than 36 0/7 weeks of gestation with intact membranes and oligohydramnios, the decision to proceed with expectant management or delivery should be individualized based on gestational age and the maternal and fetal condition. If delivery is not undertaken, follow-up amniotic fluid volume measurements, NSTs, and fetal growth assessments are indicated. If the oligohydramnios results from fetal membrane rupture, follow-up amniotic fluid volume assessment often may be safely omitted.

► ***What is the role of umbilical artery and other Doppler velocimetry studies?***

In growth-restricted fetuses, umbilical artery Doppler velocimetry used in conjunction with standard fetal surveillance, such as NSTs, BPPs, or both, is associated with improved outcomes (73, 78). Umbilical artery Doppler velocimetry has not been shown to be predictive of outcomes in fetuses without growth restriction. Investigation of other fetal blood vessels with umbilical artery Doppler



velocimetry, including assessments of the middle cerebral artery and the precordial venous system, has been explored in the setting of fetal growth restriction. However, these flow measurements have not been shown to improve perinatal outcome, and the role of these measures in clinical practice remains uncertain (see ACOG Practice Bulletin No. 227, *Fetal Growth Restriction*) (63, 73, 79–85).

► ***Should all women perform daily fetal movement assessment?***

Multiple studies have demonstrated that women who report decreased fetal movement are at an increased risk of adverse perinatal outcomes (86). Although fetal kick counting is an inexpensive test of fetal well-being, the effectiveness of kick counting in the prevention of stillbirth is uncertain (87, 88). Consistent evidence that a formal program of fetal movement assessment in low-risk women will result in a reduction in fetal deaths is lacking (89, 90). Moreover, whether fetal movement assessment adds benefit to an established program of regular fetal surveillance has not been evaluated. Formal fetal movement assessment may increase, by a small degree, the number of antepartum visits and fetal evaluations and may be associated with an increased risk of iatrogenic preterm birth, induction of labor, and cesarean birth (11). Although not all women need to perform a daily fetal movement assessment, if a woman notices a decrease in fetal activity, she should be encouraged to contact her health care provider, and further assessment should be performed.

Summary of Recommendations

Recommendations based on good and consistent scientific evidence (Level A).

- The use of the deepest vertical pocket measurement, as opposed to the amniotic fluid index, to diagnose oligohydramnios is associated with a reduction in unnecessary interventions without an increase in adverse perinatal outcomes.
- In growth-restricted fetuses, umbilical artery Doppler velocimetry used in conjunction with standard fetal surveillance, such as NSTs, BPPs, or both, is associated with improved outcomes.

Recommendations based on limited or inconsistent scientific evidence (Level B).

- Abnormal results from an NST or from a modified BPP generally should be followed by additional testing with either a CST or a BPP.

Recommendations based primarily on consensus and expert opinion (Level C).

- Initiating antepartum fetal testing at 32 0/7 weeks of gestation or later is appropriate for most at-risk patients. However, in pregnancies with multiple or particularly worrisome high-risk conditions (eg, chronic hypertension with suspected fetal growth restriction), testing might begin at a gestational age when delivery would be considered for perinatal benefit.
- When the clinical condition that prompted fetal testing persists, the testing should be repeated periodically to monitor for continued fetal well-being until delivery. If the maternal medical condition is stable and test results are reassuring, tests of fetal well-being (NST, BPP, modified BPP, or CST) are typically repeated at weekly intervals; however, in the presence of certain high-risk conditions, some investigators have performed more frequent testing, although the optimal regimen has not been established.
- In the absence of obstetric contraindications, delivery of the fetus with an abnormal test result often may be attempted by induction of labor, with continuous intrapartum monitoring of the FHR and uterine contractions.
- In the setting of otherwise uncomplicated isolated and persistent oligohydramnios (deepest vertical pocket measurement less than 2 cm), delivery at 36 0/7–37 6/7 weeks of gestation or at diagnosis if diagnosed later is recommended. In pregnancies at less than 36 0/7 weeks of gestation with intact membranes and oligohydramnios, the decision to proceed with expectant management or delivery should be individualized based on gestational age and the maternal and fetal condition.

References

1. Boddy K, Dawes GS, Fisher R, Pinter S, Robinson JS. Foetal respiratory movements, electrocortical and cardiovascular responses to hypoxaemia and hypercapnia in sheep. *J Physiol* 1974;243:599–618. (Animal)
2. Manning FA, Platt LD. Maternal hypoxemia and fetal breathing movements. *Obstet Gynecol* 1979;53:758–60. (Level III)
3. Murata Y, Martin CBJr, Ikenoue T, Hashimoto T, Taira S, Sagawa T, et al. Fetal heart rate accelerations and late decelerations during the course of intrauterine death in chronically catheterized rhesus monkeys. *Am J Obstet Gynecol* 1982;144:218–23. (Animal)
4. Natale R, Clewlow F, Dawes GS. Measurement of fetal forelimb movements in the lamb in utero. *Am J Obstet Gynecol* 1981;140:545–51. (Animal)



5. Seeds AE. Current concepts of amniotic fluid dynamics. *Am J Obstet Gynecol* 1980;138:575–86. (Level III)
6. Weiner CP, Sipes SL, Wenstrom K. The effect of fetal age upon normal fetal laboratory values and venous pressure. *Obstet Gynecol* 1992;79:713–8. (Level III)
7. Manning FA, Snijders R, Harman CR, Nicolaides K, Menticoglou S, Morrison I. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. *Am J Obstet Gynecol* 1993;169:755–63. (Level II-3)
8. Graca LM, Cardoso CG, Clode N, Calhaz-Jorge C. Acute effects of maternal cigarette smoking on fetal heart rate and fetal body movements felt by the mother. *J Perinat Med* 1991;19:385–90. (Level III)
9. Manning FA. Fetal biophysical profile: a critical appraisal. *Clin Obstet Gynecol* 2002;45:975–85. (Level III)
10. Pearson JF, Weaver JB. Fetal activity and fetal wellbeing: an evaluation. *Br Med J* 1976;1:1305–7. (Level III)
11. Bellussi F, Po' G, Livi A, Saccone G, De Vivo V, Oliver EA, et al. Fetal movement counting and perinatal mortality: a systematic review and meta-analysis. *Obstet Gynecol* 2020;135:453–62. (Systematic Review and Meta-Analysis)
12. Norman JE, Heazell AEP, Rodriguez A, Weir CJ, Stock SJ, Calderwood CJ, et al. Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial. *AFFIRM investigators. Lancet* 2018;392:1629–38. (Level I)
13. Moore TR, Piacquadio K. A prospective evaluation of fetal movement screening to reduce the incidence of antepartum fetal death. *Am J Obstet Gynecol* 1989;160:1075–80. (Level II-2)
14. Neldam S. Fetal movements as an indicator of fetal wellbeing. *Dan Med Bull* 1983;30:274–8. (Level I)
15. Huddleston JF, Sutliff G, Robinson D. Contraction stress test by intermittent nipple stimulation. *Obstet Gynecol* 1984;63:669–73. (Level III)
16. Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. I. Risk of perinatal mortality and morbidity according to antepartum fetal heart rate test results. *Am J Obstet Gynecol* 1982;143:771–7. (Level II-3)
17. Macones GA, Hankins GD, Spong CY, Hauth J, Moore T. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. *Obstet Gynecol* 2008;112:661–6. (Level III)
18. Thompson G, Newnham JP, Roberman BD, Burns SE. Contraction stress fetal heart rate monitoring at preterm gestational ages. *Aust N Z J Obstet Gynaecol* 1990;30:120–3. (Level III)
19. Freeman RK. The use of the oxytocin challenge test for antepartum clinical evaluation of uteroplacental respiratory function. *Am J Obstet Gynecol* 1975;121:481–9. (Level III)
20. Nathan EB, Haberman S, Burgess T, Minkoff H. The relationship of maternal position to the results of brief nonstress tests: a randomized clinical trial. *Am J Obstet Gynecol* 2000;182:1070–2. (Level I)
21. Clark SL, Sabey P, Jolley K. Nonstress testing with acoustic stimulation and amniotic fluid volume assessment: 5973 tests without unexpected fetal death. *Am J Obstet Gynecol* 1989;160:694–7. (Level II-3)
22. Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. *Am J Obstet Gynecol* 1996;174:812–7. (Level II-3)
23. Smith CV, Phelan JP, Platt LD, Broussard P, Paul RH. Fetal acoustic stimulation testing. II. A randomized clinical comparison with the nonstress test. *Am J Obstet Gynecol* 1986;155:131–4. (Level I)
24. Tan KH, Smyth RD, Wei X. Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD002963. DOI: 10.1002/14651858.CD002963.pub2. (Meta-analysis)
25. Evertson LR, Gauthier RJ, Schifrin BS, Paul RH. Antepartum fetal heart rate testing. I. Evolution of the nonstress test. *Am J Obstet Gynecol* 1979;133:29–33. (Level II-3)
26. Bishop EH. Fetal acceleration test. *Am J Obstet Gynecol* 1981;141:905–9. (Level II-2)
27. Lavin JP Jr, Miodovnik M, Barden TP. Relationship of nonstress test reactivity and gestational age. *Obstet Gynecol* 1984;63:338–44. (Level II-3)
28. Druzin ML, Fox A, Kogut E, Carlson C. The relationship of the nonstress test to gestational age. *Am J Obstet Gynecol* 1985;153:386–9. (Level III)
29. Cousins LM, Poeltler DM, Faron S, Catanzarite V, Daneshmand S, Casele H. Nonstress testing at ≥ 32.0 weeks' gestation: a randomized trial comparing different assessment criteria. *Am J Obstet Gynecol* 2012;207:311.e1–7. (Level I)
30. Glantz JC, Bertoia N. Preterm nonstress testing: 10-beat compared with 15-beat criteria. *Obstet Gynecol* 2011;118:87–93. (Level II-3)
31. Meis PJ, Ureda JR, Swain M, Kelly RT, Penry M, Sharp P. Variable decelerations during nonstress tests are not a sign of fetal compromise. *Am J Obstet Gynecol* 1986;154:586–90. (Level II-3)
32. Anyaegbunam A, Brustman L, Divon M, Langer O. The significance of antepartum variable decelerations. *Am J Obstet Gynecol* 1986;155:707–10. (Level II-3)
33. O'Leary JA, Andrinopoulos GC, Giordano PC. Variable decelerations and the nonstress test: an indication of cord compromise. *Am J Obstet Gynecol* 1980;137:704–6. (Level III)
34. Bourgeois FJ, Thiagarajah S, Harbert GM Jr. The significance of fetal heart rate decelerations during nonstress testing. *Am J Obstet Gynecol* 1984;150:213–6. (Level III)
35. Druzin ML, Gratacos J, Keegan KA, Paul RH. Antepartum fetal heart rate testing. VII. The significance of fetal bradycardia. *Am J Obstet Gynecol* 1981;139:194–8. (Level III)
36. Pazos R, Vuolo K, Aladjem S, Lueck J, Anderson C. Association of spontaneous fetal heart rate decelerations during antepartum nonstress testing and intrauterine growth retardation. *Am J Obstet Gynecol* 1982;144: 574–7. (Level III)



37. Manning FA, Morrison I, Lange IR, Harman CR, Chamberlain PF. Fetal biophysical profile scoring: selective use of the nonstress test. *Am J Obstet Gynecol* 1987;156:709–12. (Level II-3)
38. Chamberlain PF, Manning FA, Morrison I, Harman CR, Lange IR. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. *Am J Obstet Gynecol* 1984;150:245–9. (Level II-3)
39. Manning FA, Harman CR, Morrison I, Menticoglou SM, Lange IR, Johnson JM. Fetal assessment based on fetal biophysical profile scoring. IV. An analysis of perinatal morbidity and mortality. *Am J Obstet Gynecol* 1990;162:703–9. (Level II-3)
40. Nabhan AF, Abdelmoula YA. Amniotic fluid index versus single deepest vertical pocket as a screening test for preventing adverse pregnancy outcome. *Cochrane Database of Systematic Reviews* 2008, Issue 3. Art. No.: CD006593. DOI: 10.1002/14651858.CD006593.pub2. (Meta-analysis)
41. Magann EF, Doherty DA, Field K, Chauhan SP, Muffley PE, Morrison JC. Biophysical profile with amniotic fluid volume assessments. *Obstet Gynecol* 2004;104:5–10. (Level I)
42. Rutherford SE, Phelan JP, Smith CV, Jacobs N. The four-quadrant assessment of amniotic fluid volume: an adjunct to antepartum fetal heart rate testing. *Obstet Gynecol* 1987;70:353–6. (Level II-3)
43. Reddy UM, Abuhamad AZ, Levine D, Saade GR. Fetal imaging: executive summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. *Obstet Gynecol* 2014;123:1070–82. (Level III)
44. Erskine RL, Ritchie JW. Umbilical artery blood flow characteristics in normal and growth-retarded fetuses. *Br J Obstet Gynaecol* 1985;92:605–10. (Level III)
45. Gudmundsson S, Marsal K. Umbilical and uteroplacental blood flow velocity waveforms in pregnancies with fetal growth retardation. *Eur J Obstet Gynecol Reprod Biol* 1988;27:187–96. (Level II-3)
46. Reuwer PJ, Bruinse HW, Stoutenbeek P, Haspels AA. Doppler assessment of the fetoplacental circulation in normal and growth-retarded fetuses. *Eur J Obstet Gynecol Reprod Biol* 1984;18:199–205. (Level II-3)
47. Karsdorp VH, vanVugt JM, vanGeijn HP, Kostense PJ, Arduini D, Montenegro N, et al. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. *Lancet* 1994;344:1664–8. (Level II-2)
48. Giles WB, Trudinger BJ, Baird PJ. Fetal umbilical artery flow velocity waveforms and placental resistance: pathological correlation. *Br J Obstet Gynaecol* 1985;92:31–8. (Level II-2)
49. Nicolaides KH, Bilardo CM, Soothill PW, Campbell S. Absence of end diastolic frequencies in umbilical artery: a sign of fetal hypoxia and acidosis. *BMJ* 1988;297: 1026–7. (Level III)
50. Acharya G, Wilsgaard T, Berntsen GK, Maltau JM, Kiserud T. Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy. *Am J Obstet Gynecol* 2005;192:937–44. (Level III)
51. Almstrom H, Axelsson O, Cnattingius S, Ekman G, Maesel A, Ulmsten U, et al. Comparison of umbilical artery velocimetry and cardiotocography for surveillance of small-for-gestational-age fetuses. *Lancet* 1992;340:936–40. (Level I)
52. Johnstone FD, Prescott R, Hoskins P, Greer IA, McGlew T, Compton M. The effect of introduction of umbilical Doppler recordings to obstetric practice. *Br J Obstet Gynaecol* 1993;100:733–41. (Level I)
53. Newnham JP, O’Dea MR, Reid KP, Diepeveen DA. Doppler flow velocity waveform analysis in high risk pregnancies: a randomized controlled trial. *Br J Obstet Gynaecol* 1991;98:956–63. (Level I)
54. Omtzigt AM, Reuwer PJ, Bruinse HW. A randomized controlled trial on the clinical value of umbilical Doppler velocimetry in antenatal care. *Am J Obstet Gynecol* 1994;170:625–34. (Level I)
55. Pattinson RC, Norman K, Odendaal HJ. The role of Doppler velocimetry in the management of high risk pregnancies. *Br J Obstet Gynaecol* 1994;101:114–20. (Level I)
56. Trudinger BJ, Cook CM, Giles WB, Connelly A, Thompson RS. Umbilical artery flow velocity waveforms in high-risk pregnancy. Randomised controlled trial. *Lancet* 1987;1:188–90. (Level I)
57. Tyrrell SN, Lilford RJ, Macdonald HN, Nelson EJ, Porter J, Gupta JK. Randomized comparison of routine vs highly selective use of Doppler ultrasound and biophysical scoring to investigate high risk pregnancies. *Br J Obstet Gynaecol* 1990;97:909–16. (Level I)
58. Williams KP, Farquharson DF, Bebbington M, Dansereau J, Galerneau F, Wilson RD, et al. Screening for fetal wellbeing in a high-risk pregnant population comparing the nonstress test with umbilical artery Doppler velocimetry: a randomized controlled clinical trial. *Am J Obstet Gynecol* 2003;188:1366–71. (Level I)
59. Manning FA, Morrison I, Harman CR, Lange IR, Menticoglou S. Fetal assessment based on fetal biophysical profile scoring: experience in 19,221 referred high-risk pregnancies. II. An analysis of false-negative fetal deaths. *Am J Obstet Gynecol* 1987;157:880–4. (Level II-3)
60. Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. *Am J Obstet Gynecol* 1994;170:1672–6. (Level I)
61. Thacker SB, Berkelman RL. Assessing the diagnostic accuracy and efficacy of selected antepartum fetal surveillance techniques. *Obstet Gynecol Surv* 1986;41:121–41. (Level III)
62. Devane D, Lalor JG, Daly S, McGuire W, Cuthbert A, Smith V. Cardiotocography versus intermittent auscultation of fetal heart on admission to labour ward for assessment of fetal wellbeing. *Cochrane Database of Systematic Reviews* 2017, Issue 1. Art. No.: CD005122. DOI: 10.1002/14651858.CD005122.pub5. (Systematic Review and Meta-Analysis)



63. Indications for outpatient antepartum fetal surveillance. Committee Opinion No. 828. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2021;137:e177–97.
64. Rouse DJ, Owen J, Goldenberg RL, Cliver SP. Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach. *Am J Obstet Gynecol* 1995;173:1357–63. (Level III)
65. Lagrew DC, Pircon RA, Towers CV, Dorchester W, Freeman RK. Antepartum fetal surveillance in patients with diabetes: when to start? *Am J Obstet Gynecol* 1993;168:1820–5; discussion 1825–6. (Level II-3)
66. Pircon RA, Lagrew DC, Towers CV, Dorchester WL, Gocke SE, Freeman RK. Antepartum testing in the hypertensive patient: when to begin. *Am J Obstet Gynecol* 1991;164:1563–9; discussion 1569–70. (Level III)
67. Powers WF, Kiely JL. The risks confronting twins: a national perspective. *Am J Obstet Gynecol* 1994;170:456–61. (Level II-3)
68. Houlton MC, Marivate M, Philpott RH. The prediction of fetal growth retardation in twin pregnancy. *Br J Obstet Gynaecol* 1981;88:264–73. (Level II-3)
69. Sassoon DA, Castro LC, Davis JL, Hobel CJ. Perinatal outcome in triplet versus twin gestations. *Obstet Gynecol* 1990;75:817–20. (Level II-3)
70. Alexander JM, Hammond KR, Steinkampf MP. Multifetal reduction of high-order multiple pregnancy: comparison of obstetrical outcome with nonreduced twin gestations. *Fertil Steril* 1995;64:1201–3. (Level III)
71. Silver RK, Helfand BT, Russell TL, Ragin A, Sholl JS, MacGregor SN. Multifetal reduction increases the risk of preterm delivery and fetal growth restriction in twins: a case-control study. *Fertil Steril* 1997;67:30–3. (Level II-2)
72. Machin GA. Velamentous cord insertion in monochorionic twin gestation. An added risk factor. *J Reprod Med* 1997;42:785–9. (Level III)
73. Fetal growth restriction. ACOG Practice Bulletin No. 227. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2021;137:e16–28. (Level III)
74. Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: diagnosis and management of fetal growth restriction. Society for Maternal-Fetal Medicine (SMFM). *Am J Obstet Gynecol* 2020;223:B2–17. (Level III)
75. Staisch KJ, Westlake JR, Bashore RA. Blind oxytocin challenge test and perinatal outcome. *Am J Obstet Gynecol* 1980;138:399–403. (Level II-3)
76. Spong CY, Mercer BM, D’Alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated late-preterm and early-term birth. *Obstet Gynecol* 2011;118:323–33. (Level III)
77. Medically indicated late-preterm and early-term deliveries. ACOG Committee Opinion No. 818. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2021;137:e29–33. (Level III)
78. Alfircvic Z, Stampalija T, Dowswell T. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. *Cochrane Database of Systematic Reviews* 2017, Issue 6. Art. No.: CD007529. DOI: 10.1002/14651858.CD007529.pub4. (Systematic Review and Meta-Analysis)
79. Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. *Am J Obstet Gynecol* 2012;206:300–8. (Level III)
80. Rizzo G, Capponi A, Arduini D, Romanini C. The value of fetal arterial, cardiac and venous flows in predicting pH and blood gases measured in umbilical blood at cordocentesis in growth retarded fetuses. *Br J Obstet Gynaecol* 1995;102:963–9. (Level II-3)
81. Hecher K, Snijders R, Campbell S, Nicolaides K. Fetal venous, intracardiac, and arterial blood flow measurements in intrauterine growth retardation: relationship with fetal blood gases. *Am J Obstet Gynecol* 1995;173:10–5. (Level III)
82. Arabin B, Bergmann PL, Saling E. Simultaneous assessment of blood flow velocity waveforms in uteroplacental vessels, the umbilical artery, the fetal aorta and the fetal common carotid artery. *Fetal Ther* 1987;2:17–26. (Level III)
83. Veille JC, Kanaan C. Duplex Doppler ultrasonographic evaluation of the fetal renal artery in normal and abnormal fetuses. *Am J Obstet Gynecol* 1989;161:1502–7. (Level III)
84. Gramellini D, Folli MC, Raboni S, Vadora E, Meriardi A. Cerebral-umbilical Doppler ratio as a predictor of adverse perinatal outcome. *Obstet Gynecol* 1992;79:416–20. (Level II-3)
85. Bahado-Singh RO, Kovanci E, Jeffres A, Oz U, Deren O, Copel J, et al. The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction. *Am J Obstet Gynecol* 1999;180:750–6. (Level II-3)
86. Froen JF. A kick from within—fetal movement counting and the cancelled progress in antenatal care. *J Perinat Med* 2004;32:13–24. (Meta-analysis)
87. Management of stillbirth. ACOG Obstetric Care Consensus No. 10. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2020;135:e110–32. (Level III)
88. Grant A, Elbourne D, Valentin L, Alexander S. Routine formal fetal movement counting and risk of antepartum late death in normally formed singletons. *Lancet* 1989;2:345–9. (Level I)
89. Mangesi L, Hofmeyr GJ, Smith V, Smyth RM. Fetal movement counting for assessment of fetal wellbeing. *Cochrane Database of Systematic Reviews* 2015, Issue 10. Art. No.: CD004909. DOI: 10.1002/14651858.CD004909.pub3. Accessed December 11, 2020. (Systematic Review and Meta-Analysis)
90. Saastad E, Winje BA, Stray Pedersen B, Froen JF. Fetal movement counting improved identification of fetal growth restriction and perinatal outcomes—a multicentre, randomized, controlled trial. *PLoS One* 2011;6:e28482. (Level I)



The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1990–May 2014. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician–gynecologists were used.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

- I Evidence obtained from at least one properly designed randomized controlled trial.
- II-1 Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A—Recommendations are based on good and consistent scientific evidence.

Level B—Recommendations are based on limited or inconsistent scientific evidence.

Level C—Recommendations are based primarily on consensus and expert opinion.

Published online on May 20, 2021.

Copyright 2021 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the Internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC 20024-2188

Antepartum fetal surveillance. ACOG Practice Bulletin No. 229. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2021;137:e116–27.



This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

All ACOG committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on acog.org. For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.

